Pyxis Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Pyxis Oncology, Inc. (PYXS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.13% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-13
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.12%, a 7.42% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 3.91%.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.11%, a 13.47% decline year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.45%, a 5.20% increase year-over-year.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.45%, a 0.67% decline from fiscal 2024.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.48%, a 19.57% decline from fiscal 2023.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 5.57%, a 38.56% increase from fiscal 2022.
- Pyxis Oncology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.02%, a 195.59% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.13% 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | 4.12% 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 4.45% 10-K · filed 2026-03-23 | |||
| 2025-09-30 | 3.91% 10-Q · filed 2025-11-03 | 4.45% 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | 4.11% 10-Q · filed 2026-08-13 | 4.45% 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | 4.45% 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 4.48% 10-K · filed 2026-03-23 | |||
| 2024-09-30 | 4.48% 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | 4.75% 10-Q · filed 2025-08-14 | 4.75% 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | 4.23% 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 5.57% 10-K · filed 2025-03-18 | |||
| 2023-09-30 | 5.57% 10-Q · filed 2024-11-12 | 5.57% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 4.05% 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | 4.02% 10-K · filed 2024-03-21 | |||
| 2022-09-30 | 4.02% 10-Q · filed 2023-11-07 | 4.02% 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | 3.34% 10-Q · filed 2023-08-11 | 3.34% 10-Q · filed 2023-08-11 | ||
| 2021-12-31 | 1.36% 10-K · filed 2023-03-22 | |||
| 2021-09-30 | 0.96% 10-Q · filed 2022-11-01 | 1.16% 10-Q · filed 2022-11-01 | ||
| 2021-06-30 | 1.16% 10-Q · filed 2022-08-15 | |||
| 2020-12-31 | 0.56% 10-K · filed 2022-03-29 | |||
| 2020-09-30 | 0.38% 10-Q · filed 2021-11-15 | 0.56% 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |